Prof Lucy Dorrell

Prof Lucy Dorrell

Lucy Dorrell is an Associate Professor, Senior Clinical Research Fellow and Honorary Consultant in Genitourinary / HIV Medicine at the Nuffield Department of Medicine

Prof Lucy Dorrell previously held research fellowships at Imperial College London, MRC Laboratories, The Gambia and the University of Oxford. Lucy is a Member of Congregation, Supervisor, Group Head / PI and Consultant Physician.

The focus of Lucy Dorrell’s Research Group is the development of vaccines and T cell-based therapies for prevention and eradication of HIV, HIV / hepatitis C co-infections and high risk human papillomavirus infections (HR HPV). She has conducted clinical trials of HIV vaccine candidates that exploit a potent viral vector prime-boost platform  for immunogen delivery in healthy volunteers and antiretroviral therapy-treated patients. She has recently started to develop a new multi-genotype HPV vaccine for therapy of cervical dysplasia (pre-cancer).

This work is complemented by laboratory-based research to identify immune correlates of virus control or clearance. Her group has developed CD8+ T cell viral inhibition assays and shown that these predict immune control of HIV in vivo and can be applied to the evaluation of vaccines and T cell-based drugs. She will now conduct a longitudinal study in 400 women to investigate the development of adaptive immune responses to HR HPV.


Selected Publications

Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, Payne TL, Berrong M, Ferrari G, Chopera D, Hanke T, Mothe B, Brander C, McElrath MJ, McMichael A, Goonetilleke N, Tomaras GD, Frahm N, Dorrell L. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. Plos Pathogens 2015, Feb 27.

Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, Hayton EJ, Black A, Bridgeman A, Rosario M, Hill AV, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L, Hanke T. Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Mol Ther. 2014; 22: 464-75.

Yang H, Wu H, Hancock G, Clutton G, Sande N, Xu X, Yan H, Huang X, Angus B, Kuldanek K, Fidler S, Denny TN, Birks J, McMichael A, Dorrell L. The antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ cell decline in HIV-1 infection. J Infect Dis 2012, 206: 552-61.